Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model

Oncolytic virotherapy (OVT) is now understood to be an immunotherapy that uses viral infection to liberate tumor antigens in an immunogenic context to promote the development of antitumor immune responses. The only currently FDA-approved oncolytic virotherapy, T-Vec, is a modified type 1 herpes simp...

Descripción completa

Detalles Bibliográficos
Autores principales: Uche, Ifeanyi Kingsley, Fowlkes, Natalie, Vu, Luan, Watanabe, Tatiane, Carossino, Mariano, Nabi, Rafiq, del Piero, Fabio, Rudd, Jared S., Kousoulas, Konstantin G., Rider, Paul J. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Cellular Response to Infection
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925097/
https://www.ncbi.nlm.nih.gov/pubmed/33177208
http://dx.doi.org/10.1128/JVI.01359-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925097/
https://www.ncbi.nlm.nih.gov/pubmed/33177208
http://dx.doi.org/10.1128/JVI.01359-20

Ejemplares similares